2024-03-29T14:09:48Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/139582023-04-28T18:49:59Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2053com_20.500.12105_2052col_20.500.12105_16982col_20.500.12105_16978col_20.500.12105_16938col_20.500.12105_2054
00925njm 22002777a 4500
dc
Berenguer, Juan
author
Rivero, Antonio
author
Jarrin-Vera, Inmaculada
author
Núñez, María J
author
Vivancos, María J
author
Crespo, Manel
author
Téllez, María Jesús
author
Domingo, Pere
author
Iribarren, José A
author
Artero, Arturo
author
Márquez, Manuel
author
Santos, Ignacio
author
Moreno, Javier
author
Montero, Marta
author
González-García, Juan
author
GeSIDA 8514 Study Group
author
2016-03
Background: The purpose of this study was to assess the prevalence of anti-hepatitis C virus (HCV) antibodies (Abs) and active HCV infection in human immunodeficiency virus (HIV)-infected (HIV+) patients in Spain in 2015. This was a cross-sectional study. Methods: The study was performed in 41 centers in 2015. Sample size was estimated for an accuracy of 2%, the number of patients from each hospital was determined by proportional allocation, and patients were selected using simple random sampling. Results: The reference population was 35 791 patients, and the sample size was 1867 patients. Hepatitis C virus serostatus was known in 1843 patients (98.7%). Hepatitis C virus-Abs were detected in 695 patients (37.7%), in whom the main route of HIV acquisition was injection drug use (75.4%). Of these 695 patients, 402 had HCV RNA, 170 had had a sustained viral response (SVR) after anti-HCV therapy, and 102 cleared HCV spontaneously. Hepatitis C virus-ribonucleic acid results were unknown in 21 cases. Genotype distribution (known in 367 patients) was 1a in 143 patients (39.0%), 4 in 90 (24.5%) patients, 1b in 69 (18.8%) patients, 3 in 57 (15.5%) patients, 2 in 5 (1.4%) patients, and mixed in 3 (0.8%) patients. Liver cirrhosis was present in 93 patients (23.1%) with active HCV infection and in 39 (22.9%) patients with SVR after anti-HCV therapy. Conclusions: The prevalence of HCV-Abs and active HCV infection in HIV+ patients in Spain is 37.7% and 22.1%, respectively; these figures are significantly lower than those recorded in 2002 and 2009. The predominant genotypes in patients with active HCV infection were 1a and 4. A high percentage of patients had cirrhosis. Cirrhosis is also common in patients with SVR after anti-HCV therapy.
Open Forum Infect Dis. 2016;3(2):ofw059.
2328-8957
http://hdl.handle.net/20.500.12105/13958
27186584
10.1093/ofid/ofw059
Open Forum Infectious Diseases
HIV infections/epidemiology
Spain/epidemiology
Coinfection/epidemiology
Hepatitis C/drug therapy/epidemiology
Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics